Tralokinumab-Ldrm
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis.
Journal: Journal of comparative effectiveness research
Published: June 09, 2026
Comparison chart: Interleukin (IL) antagonists and oral JAK inhibitors for moderate to severe atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Nemolizumab (Nemluvio) for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Comparison chart: Interleukin (IL) receptor antagonists for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Lebrikizumab (Ebglyss) for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: November 07, 2024
Three drugs for atopic dermatitis (Adbry, Cibinqo, and Rinvoq).
Journal: The Medical letter on drugs and therapeutics
Published: April 06, 2023
Tralokinumab-ldrm.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: March 10, 2022
Tralokinumab in Atopic Dermatitis: A Profile of Its Use.
Journal: Clinical drug investigation
Published: February 20, 2022
Showing 1-10 of 10
Last Updated: 06/30/2026